Enanta Pharmaceuticals
(NASDAQ) ENTA
Enanta Pharmaceuticals Financials at a Glance
Market Cap
$363.03M
Revenue (TTM)
$66.98M
Net Income (TTM)
$71.54M
EPS (TTM)
$-3.20
P/E Ratio
-3.90
Dividend
$0.00
Beta (Volatility)
1.01 (Average)
Dividend
$0.00
Beta (Volatility)
1.01 (Average)
Price
$12.53
Volume
2,788
Open
$13.22
Price
$12.53
Volume
2,788
Open
$13.22
Previous Close
$12.53
Daily Range
$12.48 - $13.22
52-Week Range
$4.09 - $17.15
Dividend
$0.00
Beta (Volatility)
1.01 (Average)
Price
$12.53
Volume
2,788
Open
$13.22
Previous Close
$12.53
Daily Range
$12.48 - $13.22
52-Week Range
$4.09 - $17.15
ENTA News
ENTA: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Enanta Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
120
CEO
Jay R. Luly, PhD
Website
www.enanta.comHeadquarters
Watertown, MA 02472, US
ENTA Financials
Key Financial Metrics (TTM)
Gross Margin
100%
Operating Margin
-1%
Net Income Margin
-1%
Return on Equity
-60%
Return on Capital
-26%
Return on Assets
-22%
Earnings Yield
-25.64%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$363.03M
Shares Outstanding
29.02M
Volume
2.79K
Short Interest
0.00%
Avg. Volume
228.83K
Financials (TTM)
Gross Profit
$60.74M
Operating Income
$85.35M
EBITDA
$70.78M
Operating Cash Flow
$19.27M
Capital Expenditure
$12.90M
Free Cash Flow
$32.17M
Cash & ST Invst.
$188.86M
Total Debt
$201.06M
Enanta Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$18.61M
+9.8%
Gross Profit
$18.61M
+9.8%
Gross Margin
100.00%
N/A
Market Cap
$363.03M
N/A
Market Cap/Employee
$2.77M
N/A
Employees
131
N/A
Net Income
$11.94M
+46.4%
EBITDA
$7.60M
+61.7%
Quarterly Fundamentals
Net Cash
$7.33M
-59.5%
Accounts Receivable
$8.49M
-78.9%
Inventory
$0.00
N/A
Long Term Debt
$157.91M
-15.8%
Short Term Debt
$35.27M
+4.5%
Return on Assets
-21.71%
N/A
Return on Invested Capital
-25.65%
N/A
Free Cash Flow
$11.84M
+53.6%
Operating Cash Flow
$11.70M
+30.4%